AU
UK
CA
US
IND
NZ
Last update at 2026-06-12T17:56:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
ASX Penny Stocks To Watch In April 2026
Thu 02 Apr 26, 03:05 AMASX Penny Stocks Spotlight Bravura Solutions And Two Others
Wed 11 Feb 26, 08:02 PMInsider Buying Highlights Asian Undervalued Small Caps For January 2026
Thu 01 Jan 26, 10:36 PMBravura Solutions And 2 Other ASX Penny Stocks To Watch
Tue 23 Dec 25, 03:05 AMASX Penny Stocks Spotlight: Bravura Solutions And 2 More To Watch
Mon 24 Nov 25, 03:04 AM3 Promising ASX Penny Stocks With Over A$80M Market Cap
Tue 18 Nov 25, 08:02 PMDiscover 3 ASX Penny Stocks With Market Caps Under A$2B
Tue 14 Oct 25, 03:05 AMASX Penny Stocks To Watch In September 2025
Tue 02 Sep 25, 03:05 AM3 Promising ASX Penny Stocks With Market Caps Under A$2B
Mon 01 Sep 25, 08:02 PM3 ASX Penny Stocks Under A$700M Market Cap To Watch
Mon 01 Sep 25, 03:05 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 25.71M | -49.12600M | -121.11100M | -263.89900M | 7.62M |
| Minority interest | -4.54200M | 10.29M | 50.78M | 54.69M | -9.78900M |
| Net income | 22.73M | -33.54200M | -156.23000M | -213.39100M | 9.59M |
| Selling general administrative | 314.03M | 322.67M | 300.03M | 33.92M | 255.08M |
| Selling and marketing expenses | - | 4.42M | 3.85M | 42.90M | - |
| Gross profit | 382.43M | 388.23M | 328.19M | 331.08M | 302.71M |
| Reconciled depreciation | 47.01M | 49.55M | 73.25M | 66.80M | 34.88M |
| Ebit | 58.55M | -10.33400M | -80.43500M | -35.67600M | 17.72M |
| Ebitda | 105.56M | 39.22M | -23.07000M | 31.13M | 52.60M |
| Depreciation and amortization | 47.01M | 49.55M | 57.37M | 66.80M | 34.88M |
| Non operating income net other | - | - | - | - | -3.32900M |
| Operating income | 58.55M | -11.97900M | -81.72500M | -35.67600M | 17.72M |
| Other operating expenses | 509.54M | 585.26M | 594.07M | 560.74M | 409.85M |
| Interest expense | 26.49M | 38.79M | 40.68M | 25.80M | 1.11M |
| Tax provision | -1.56500M | -5.29300M | -16.26200M | -50.50800M | -1.96600M |
| Interest income | - | - | - | - | - |
| Net interest income | -26.48600M | -38.79200M | -51.55900M | -25.79500M | -1.11200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | 8.16M |
| Other items | - | - | - | - | - |
| Income tax expense | -1.56500M | -5.29300M | 0.09M | -50.50800M | -1.96600M |
| Total revenue | 568.09M | 573.28M | 512.35M | 512.12M | 430.90M |
| Total operating expenses | 323.88M | 400.20M | 409.92M | 379.70M | 281.65M |
| Cost of revenue | 185.66M | 185.05M | 184.15M | 181.04M | 128.19M |
| Total other income expense net | -32.83800M | -37.14700M | -39.38600M | -228.22300M | -10.10200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 27.27M | -43.83300M | -203.75700M | -213.39100M | 9.59M |
| Net income applicable to common shares | - | - | - | - | 19.38M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 683.56M | 727.96M | 810.91M | 1372.65M | 1225.86M |
| Intangible assets | 368.42M | 404.73M | 482.35M | 1038.72M | 695.19M |
| Earning assets | - | - | - | - | - |
| Other current assets | 11.06M | 14.16M | 16.66M | 18.68M | 27.24M |
| Total liab | 455.11M | 542.35M | 589.79M | 1032.32M | 692.07M |
| Total stockholder equity | 184.10M | 147.94M | 173.59M | 316.58M | 458.92M |
| Deferred long term liab | - | - | - | - | 133.52M |
| Other current liab | 130.24M | 155.50M | 115.81M | 233.41M | 3.56M |
| Common stock | 0.08M | 0.08M | 0.08M | 0.08M | 0.07M |
| Capital stock | 0.08M | 0.08M | 0.08M | 0.08M | 0.07M |
| Retained earnings | -334.92900M | -355.07800M | -321.53600M | -165.30600M | -6.60200M |
| Other liab | - | - | - | - | 171.57M |
| Good will | 7.46M | 7.46M | 7.46M | 13.76M | 147.62M |
| Other assets | - | - | - | - | 50.48M |
| Cash | 51.24M | 41.58M | 36.96M | 31.81M | 43.93M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 160.38M | 210.40M | 175.50M | 304.02M | 180.86M |
| Current deferred revenue | - | - | 4.75M | - | 142.35M |
| Net debt | 260.11M | 294.05M | 372.51M | 386.25M | 313.75M |
| Short term debt | 19.21M | 27.34M | 31.91M | 33.06M | 18.04M |
| Short long term debt | 15.00M | 27.34M | 27.85M | 33.06M | 18.04M |
| Short long term debt total | 311.35M | 335.63M | 409.48M | 418.07M | 357.68M |
| Other stockholder equity | 520.85M | 505.51M | 494.25M | 481.92M | 465.27M |
| Property plant equipment | - | - | - | - | 22.98M |
| Total current assets | 272.84M | 275.61M | 268.00M | 272.57M | 263.10M |
| Long term investments | - | - | - | 2.64M | 29.29M |
| Net tangible assets | - | - | - | - | -383.89200M |
| Short term investments | - | - | - | - | - |
| Net receivables | 128.30M | 127.39M | 123.05M | 136.65M | 124.96M |
| Long term debt | 278.95M | 308.29M | 367.00M | 385.01M | 339.64M |
| Inventory | 82.24M | 92.47M | 91.33M | 85.41M | 61.69M |
| Accounts payable | 10.93M | 23.69M | 23.04M | 37.55M | 16.91M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | 74.86M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1.90000M | -2.57300M | 0.79M | -0.11000M | 0.18M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 0.07M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | -6.60200M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.29M | 1.89M | 3.14M | -154.00100M | 50.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 410.72M | 452.35M | 542.91M | 1100.07M | 962.76M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00000M | 22.96M | 12.99M | -116.43600M | -13.52000M |
| Change to liabilities | - | - | - | - | 18.21M |
| Total cashflows from investing activities | -3.24800M | 22.96M | 15.81M | - | -283.76000M |
| Net borrowings | -42.91000M | -59.58400M | -23.26400M | - | 166.20M |
| Total cash from financing activities | -61.44300M | -54.58000M | -26.65300M | 62.08M | 273.37M |
| Change to operating activities | - | - | - | - | -13.27700M |
| Net income | 22.73M | -0.31800M | -121.19600M | -213.39100M | 9.59M |
| Change in cash | 9.66M | 4.62M | 5.13M | -67.37600M | 12.37M |
| Begin period cash flow | 41.58M | 36.96M | 31.84M | 99.21M | 86.84M |
| End period cash flow | 51.24M | 41.58M | 36.96M | 31.84M | 99.21M |
| Total cash from operating activities | 73.98M | 38.80M | 15.34M | -13.53700M | 22.99M |
| Issuance of capital stock | 2.07M | 2.44M | 1.70M | 5.82M | 109.41M |
| Depreciation | 47.01M | 49.55M | 57.37M | 66.80M | 34.88M |
| Other cashflows from investing activities | -3.24800M | 23.97M | -11.50600M | - | -262.87000M |
| Dividends paid | - | - | - | 0.00000M | -0.36700M |
| Change to inventory | 8.57M | -16.43500M | -5.99100M | -18.61800M | 3.18M |
| Change to account receivables | -0.91600M | -10.66600M | 10.05M | -18.02200M | -20.05200M |
| Sale purchase of stock | - | - | - | - | 277.45M |
| Other cashflows from financing activities | -20.60700M | 2.56M | -4.16700M | 101.29M | -1.87500M |
| Change to netincome | - | - | - | - | 11.89M |
| Capital expenditures | 2.56M | 1.01M | 7.36M | 11.52M | 7.37M |
| Change receivables | - | - | - | - | -20.05200M |
| Cash flows other operating | - | - | - | - | -25.12000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | 12.60M |
| Change in working capital | -13.84000M | -11.78000M | -3.18100M | -14.53200M | -13.27700M |
| Stock based compensation | 12.67M | 10.06M | 2.72M | 17.59M | -4.51200M |
| Other non cash items | 87.82M | -3.32600M | 82.01M | 182.79M | 6.08M |
| Free cash flow | 71.41M | 37.79M | 7.98M | -25.05700M | 15.62M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BVS Bioventus Inc |
-0.025 0.29% | 8.65 | 29.21 | 12.76 | 1.14 | 3.52 | 1.57 | 8.99 |
| ABT Abbott Laboratories |
-1.875 2.09% | 87.78 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
8.31 2.72% | 313.95 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.035 0.04% | 80.30 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.235 0.50% | 46.94 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
4721 Emperor Boulevard, Durham, NC, United States, 27703
| Name | Title | Year Born |
|---|---|---|
| Mr. Kenneth M. Reali | CEO & Director | 1966 |
| Mr. Mark Singleton | Sr. VP, CFO & Principal Accounting Officer | 1969 |
| Mr. Anthony James | VP of Operations and Quality | NA |
| Mr. Miguel O. Beltran-Delgado | Sr. VP of Operations | NA |
| Ms. Alessandraa Pavesio | Sr. VP & Chief Science Officer | 1967 |
| Mr. David Crawford | VP of Investor Relations & Treasurer | NA |
| Mr. Anthony D'Adamio | Sr. VP, Gen. Counsel & Corp. Sec. | 1961 |
| Ms. Katrina J. Church | Sr. VP & Chief Compliance Officer | 1962 |
| Mr. Jeff Welch | VP of Bus. Devel. | NA |
| Mr. Christopher K. Yamamoto | Sr. VP of Corp. Devel. & Strategy | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...